Breaks Categories: News

TuesdayFeb 16, 2021 12:07 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters Licensing Deal with Taste-T LLC

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, has announced its licensing deal with U.S. based Taste-T LLC. According to the update, Taste-T utilizes a proprietary manufacturing system to produce and package branded cannabis gummies and sells them in multiple U.S. states including Nevada, Massachusetts, Michigan and Oklahoma. Their famous products come in unique blister packaging and include Margarita Chill and Fireball Cinnamon. Pure Extracts has signed an agreement with exclusive rights for Canada and first rights to other countries around the world. Included…

Continue Reading

WednesdayFeb 10, 2021 10:14 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Studying Potential for Psychedelics in Treatment of Mental Health Conditions, Announces Addition of Mescaline to Subsidiary Medicine Programs

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, is involved in preclinical laboratory work designed to study a variety of psychotropic compounds, including psilocybin, mescaline, LSD, MDMA and DMT. The company also announced that its subsidiary, XPhyto Laboratories Inc., has added the production of mescaline to its psychedelic medicine programs. These psychedelic compounds show promising potential in treating mental conditions because they are known to modulate neurotransmitters such as serotonin and dopamine, which regulate cognition, perception and mood in individuals. Called a leader in innovating psychedelic drugs in a recent…

Continue Reading

WednesdayFeb 10, 2021 10:04 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces First Commercial Contract for CBD Oil

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has contracted for its initial commercial CBD oil sale. The company anticipated the contract will result in multiple shipments of its 85% pure CBD distillate offering this year. Pure Extracts’ state-of-the-art, subcritical/super-critical CO2 extraction system produces an exceptionally pure THC and CBD full-spectrum oil and distillate. The resulting distillate can be used to manufacture a variety of cannabis 2.0 products, such as beverages, edibles and vape pens. The announcement also noted that Pure Extracts continues its commitment to increase awareness.…

Continue Reading

WednesdayFeb 03, 2021 11:48 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Publication of Article Led by CEO Dr. Roger McIntyre

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) today announced the publication of an article led by its CEO Dr. Roger McIntyre. The article, titled, “The Rapid Mood Screener (‘RMS’): a novel and pragmatic screener for bipolar I disorder,” is published at Taylor and Francis.com. "Timely and accurate diagnoses are precursors of good clinical outcomes in persons with treatment-resistant mood disorders, the high rate of missed bipolar disorder diagnosis is a critical unmet need," stated Dr. Roger McIntyre. "The Rapid Mood Screener provides a systematic approach to screening for bipolar disorder amongst all patients who present with depressive symptoms. It…

Continue Reading

WednesdayFeb 03, 2021 11:06 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Signs Production Agreement with Applied Pharmaceutical Innovation

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has signed an agreement with Applied Pharmaceutical Innovation. A not-for-profit institution at the University of Alberta, Applied supports translational drug development for industry and innovators. XPhyto’s psychedelic pharmaceutical production agreement calls for the synthesis of pharmaceutical-grade psychedelic compounds and the development of the standard operating procedures required to obtain regulatory approval for the commercial production process. As part of its psychedelic pharmaceutical program, XPhyto needs industrial-scale production of standardized active pharmaceutical ingredients. This agreement is part of that strategic…

Continue Reading

WednesdayFeb 03, 2021 10:39 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Completes New Company Registration for Class 1 NPN

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company specializing in cannabis, hemp and mushroom products, announced that it has completed its application for new company registration with the Natural and Non-prescription Health Products Directorate (“NNHPD”) and subsequently has received its company code. As a result, Pure Extracts can now submit an application for a Class 1 Natural Product Number (“NPN”) for a functional mushroom product. PULL anticipates this will be the first of several NPN applications it submits in 2021. The applications are part of Pure Extracts strategic plan to sell functional mushroom wellness products through…

Continue Reading

WednesdayJan 27, 2021 1:52 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp.’s (CSE: PULL) (OTC: PRXTF) US Shares Gain DTC Eligibility

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF), a plant-based extraction company specializing in cannabis, hemp and mushroom products, this morning announced that its common shares on the OTC Market under the symbol "PRXTF" are now eligible for electronic clearing and settlement through The Depository Trust Company ("DTC"). “DTC eligibility is a major step forward in increasing liquidity, broadening our shareholder base and building a strong presence for our company within the US capital markets sphere. This is an important step in amplifying our story to a wider audience,” Pure Extracts CEO Ben Nikolaevsky stated in the news release. To view…

Continue Reading

TuesdayJan 26, 2021 10:27 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) Announces Biomass Purchase Agreements to Scale-Up Extract Production

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has entered into its first initial substantial biomass purchase agreements; the agreements are designed to support an increase in the company’s production of THC and CBD oil extracts. Executed with a large Canadian Licensed Producer, one purchase agreement outlines Pure Extracts’ intent to purchase 220 kgs of high-potency THC cannabis dried flower; the company also agreed to purchase approximately 1,000 kgs of high-potency CBD biomass from a top Western Canada cultivator. The company plans to use the cannabis to produce full-spectrum (“FSO”) THC…

Continue Reading

MondayJan 25, 2021 11:25 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) Opens New CRTCE Clinic to Provide Ketamine Treatment for Adults with Depression

Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions, has opened its third Canadian Rapid Treatment Center of Excellence (“CRTCE”) clinic. Champignon chairman and CEO Roger McIntyre announced the opening of the center; the announcement noted that the clinics — the other two are located in Mississauga and Toronto — are focused on the treatment of depression and suicide through novel ketamine therapy treatment. The company noted in the announcement that more than 20 clinical trials have been conducted that demonstrate the effectiveness of ketamine and…

Continue Reading

ThursdayJan 21, 2021 3:34 pm

PsychedelicNewsBreaks – Following a Year of Success, Psychedelics Could Emerge Large in 2021

The year 2020 was a great year for psychedelics; more than two dozen companies focusing on psychedelics in some manner became publicly listed. That success certainly seems to have sparked interest in what the sector will see in 2021. A recent Benzinga article, titled “What Will the Psychedelics Space Look Like in 2021? Experts Weigh In” noted that as psychedelics grow closer to receiving federal legalization, scientific, regulatory and corporate developments are almost daily news. Experts in the field are looking for new clinical and R&D initiatives to emerge, investment opportunities to increase, and public acceptance to expand. In addition,…

Continue Reading